Ambition
AMBITION
Servier 2030: laying the foundations for future success
Global therapeutic needs are immense. We strive to play our part in satisfying them in our therapeutic areas (oncology, cardiometabolism and venous diseases, neurology and immuno-inflammation).
Our Servier 2030 strategy engages the entire Group. The past year has shown the goals we have set are achievable, we may even exceed them. Servier 2030 is structured around four pillars.
By 2030, Servier aims to be:
Be an innovative and patient-driven business with a rich pipeline
At Servier, we put patients at the heart of our innovation strategy. In oncology in particular, we are an innovative player in treating rare cancers, such as certain digestive, brain and blood cancers. In cardiometabolism and venous diseases, we pursue incremental innovation and develop Single Pill Combinations, which make it easier for patients prescribed multiple medications to follow their treatment plan and thereby improve adherence. Our efforts also center around developing digital solutions that also help patients stick to their treatment. Furthermore, we aim to develop a third therapeutic area, in addition to oncology and cardiovascular, metabolism and venous diseases – neurology, an area in which needs are on the rise.
This strategy is applied through our One Innovation Engine approach, which involves seeking out and taking advantage of the most promising technological and scientific opportunities, both within the Group and beyond, to further our therapeutic objectives and ultimately benefit patients.
The Group thereby aims to:
Be a resilient, growing and highly profitable company
With an increased annual revenue objective for 2030, Servier continues to pursue an ambitious, targeted growth strategy. It is in oncology, in the US in particular, that we expect to achieve the most rapid growth, driven by an acceleration in therapeutic innovation. We aim to generate revenue of €4 billion in oncology and neurology by 2030. This ambition is achievable in light of our current performance. Indeed, having notched up €1.43 billion in oncology revenue for 2023-2024, we are already outperforming our initial objective of €1 billion for 2024-2025.
In cardiometabolism and venous diseases, we aim to consolidate our position (5th globally in cardiology and 1st in hypertension outside the US and Japan(1)) by developing Single Pill Combinations and our Beyond the Pill approach (see Adherence to treatment – when every pill matters, p. 18-21). This strategy goes hand in hand with maintaining vast geographical coverage that integrates emerging countries.
This orientation should enable us to achieve global revenue of €10 billion by 2030, split as follows:
These figures, which include an EBITDA target of at least 30% of revenue, reflect our confidence in our ability to effectively implement our strategy. We believe strong financial results demonstrate our resilience, as they enable us to reinvest our profits back into research and development, thereby guaranteeing our long-term independence. We are on the right track as our EBITDA target of €1.3 billion set for 2025 has already been exceeded by €0.1 billion, having registered €1.4 billion (24.3% of revenue) in 2023-2024.
A positive force in society, creating a measurable impact
As a pharmaceutical Group, the importance we give to patient health is key. The health of our employees, the communities around us and the planet is just as important. Corporate social responsibility is included in Servier’s by-laws, lastingly binding all entities throughout the Group. We live up to our pledge by launching a major CSR project every three years. The first such project, initiated in 2023, focused on pediatric cancers. It seeks to increase the survival rate of children with cancer globally, in accordance with the goals set out by the World Health Organization. We aim to make a significant impact through this project by 2027.
As we strongly believe that in the absence of a healthy environment, there can be no true health, we also strive to protect the planet by reducing our carbon footprint, preserving biodiversity and integrating ecodesign into our medicines (see A healthy environment, fundamental to human health, p. 22-23).
Be an attractive company, for which its employees are proud and passionate to work
We put employees at the heart of everything we do. To ensure Servier 2030 is a success, we strive to foster a working environment that promotes engagement, improves retention and attracts talent. Our Pulse engagement survey conducted in May 2024 with the Gallup Institute found that 67% of employees felt engaged, up 1 point on the previous year. The overall engagement score came out at 4.33/5 (compared with 4.32 in 2023) with a 91% participation rate. This result reflects the vitality of our collective action to bolster the ties between our teams and boost wellbeing at work.
Moreover, we were honored to receive the Gallup Exceptional Workplace Award in 2024, thereby becoming the first company in France to receive such a distinction. Such recognition represents an endorsement of our commitment to our employees and corporate culture, where the level of engagement among our teams is 11 times greater than the global average, reflecting how our corporate culture centers around wellbeing and collective involvement.
1 IQVIA, Analytics Link / World 75 countries – MAT Q2-2024